ArticleJournal of cardiovascular and thoracic research2026
Mid-term outcomes associated with thoracic endovascular aortic repair and differences in outcomes for thoracic aortic aneurysms versus type B aortic dissections.
Article in Journal of cardiovascular and thoracic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thoracic endovascular aortic repair (TEVAR) has become the preferred treatment modality of thoracic aortic pathologies. Since survival outcomes are influenced by disease acuity and pathology, we aim to compare mid-term outcomes of TEVAR in the management of thoracic aortic aneurysms (TAA) vs. Stanford type-B aortic dissections (TBAD). Methods: Patients undergoing TEVAR (2010-2019) in the Vascular Quality Initiative-Medicare-linked database were included in this analysis. Patients were divided into two groups: TAA and TBAD. Postoperative outcomes included 30-day mortality, stroke, myocardial infarction (MI), and spinal cord ischemia (SCI). Mid-term outcomes included 1 and 2-year all-cause mortality, reintervention and rupture. Results: Of the 2105 patients undergoing TEVAR in this analysis, 1,492 (70.9%) had TAA while 613 (29.1%) had TBAD. The TBAD group had a significantly lower 30-day mortality (aOR:0.67,95%Cl:0.46-0.98, Conclusion: In this large multi-institutional study, patients undergoing TEVAR for TBAD had significantly lower postoperative mortality but a higher risk of reintervention at one and two years compared to patients with TAA. Additionally, both groups demonstrated a similar risk of rupture at both 1 and 2 years post-TEVAR. The rate of post-TEVAR rupture in both groups underscore the need for careful follow-up and reintervention as needed to maintain the integrity of the repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.